Youfang Xun1, Qing Cao2, Jingxian Zhang3, Bing Guan4, Maohua Wang5. 1. Department of Otolaryngology, Head and Neck Surgery, XiangYa School of Medicine, Central South University, Changsha 410000, Hunan Province, People's Republic of China. 2. Department of Otolaryngology, Head and Neck Surgery, Clinical Medical College, Yangzhou University, Yangzhou 225001, Jiangsu Province, People's Republic of China. 3. Department of Otolaryngology, Head and Neck Surgery, Dalian Medical University, Dalian 116000, Liaoning Province, People's Republic of China. 4. Department of Otolaryngology, Head and Neck Surgery, Clinical Medical College, Yangzhou University, Yangzhou 225001, Jiangsu Province, People's Republic of China. Electronic address: aliceguan0685@sina.com. 5. Department of Otolaryngology, Head and Neck Surgery, XiangYa School of Medicine, Central South University, Changsha 410000, Hunan Province, People's Republic of China. Electronic address: jameswang@csu.edu.cn.
Abstract
BACKGROUND: The prognostic significance of circulating tumor cells (CTCs) in patients with head and neck squamous cell carcinoma (HNSCC) is still unclear. The objective of this study was to estimate its correlation with clinicopathological and prognostic significance in HNSCC. MATERIALS AND METHODS: Two authors systematically searched the studies independently with keywords in PubMed, Web of science, Embase, the Cochrane database, the CNKI database, the Science citation index and the references of relevant studies (up to February 2019). Odds ratio (OR), risk ratio (RR), pooled hazard ratio (HR) and 95% confidence intervals (95%CI) were calculated as effect values. RESULTS: Twenty studies containing 1054 patients with HNSCC were included in this meta-analysis. The CTC-positive rate was higher in the T3-T4 group (RR = 1.29, 95% CI [1.11, 1.49], I2 = 47.3%), the N1-N3 group (RR = 1.18, 95% CI [1.02, 1.36], I2 = 12.4%) and the III-IV group (RR = 1.13, 95% CI [1.02, 1.25], I2 = 0%). Positive CTCs were significant associated with overall survival (HR = 1.37, 95% CI [0.59, 2.15], I2 = 9.7%), progression-free survival (HR = 3.40, 95%CI [1.47, 5.32], I2 = 0%), and disease-free survival (HR = 3.57, 95%CI [1.06, 6.08], I2 = 81%). CONCLUSION: Our meta-analysis results indicated that CTCs are significant associated with prognosis of patients with HNSCC. The presence of CTCs can be used as a monitoring tool for survival prognosis of HNSCC patients in the future.
BACKGROUND: The prognostic significance of circulating tumor cells (CTCs) in patients with head and neck squamous cell carcinoma (HNSCC) is still unclear. The objective of this study was to estimate its correlation with clinicopathological and prognostic significance in HNSCC. MATERIALS AND METHODS: Two authors systematically searched the studies independently with keywords in PubMed, Web of science, Embase, the Cochrane database, the CNKI database, the Science citation index and the references of relevant studies (up to February 2019). Odds ratio (OR), risk ratio (RR), pooled hazard ratio (HR) and 95% confidence intervals (95%CI) were calculated as effect values. RESULTS: Twenty studies containing 1054 patients with HNSCC were included in this meta-analysis. The CTC-positive rate was higher in the T3-T4 group (RR = 1.29, 95% CI [1.11, 1.49], I2 = 47.3%), the N1-N3 group (RR = 1.18, 95% CI [1.02, 1.36], I2 = 12.4%) and the III-IV group (RR = 1.13, 95% CI [1.02, 1.25], I2 = 0%). Positive CTCs were significant associated with overall survival (HR = 1.37, 95% CI [0.59, 2.15], I2 = 9.7%), progression-free survival (HR = 3.40, 95%CI [1.47, 5.32], I2 = 0%), and disease-free survival (HR = 3.57, 95%CI [1.06, 6.08], I2 = 81%). CONCLUSION: Our meta-analysis results indicated that CTCs are significant associated with prognosis of patients with HNSCC. The presence of CTCs can be used as a monitoring tool for survival prognosis of HNSCC patients in the future.
Authors: Lilian N Ruiter; Boukje A C van Dijk; Annette H Bruggink; Patricia A H Doornaert; Marielle E P Philippens; Remco de Bree; Carla H van Gils; Stefan M Willems Journal: BMC Cancer Date: 2022-04-22 Impact factor: 4.638